Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra, Ashok Kumar Das, Rakesh Sahay, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1645-1717
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Calvin Ke, K.M. Venkat Narayan, Juliana C.N. Chan, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 7, pp. 413-432
Open Access | Times Cited: 147
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Åhrén, Stephen L. Atkin, G. Charpentier, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 9, pp. 2210-2219
Open Access | Times Cited: 110
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 49
Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model
Shafei Zhai, Changkui Liu, Selvaraj Vimalraj, et al.
Peptides (2023) Vol. 163, pp. 170974-170974
Closed Access | Times Cited: 16
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Sanjay Kalra, Rakesh Sahay
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1965-1982
Open Access | Times Cited: 42
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
Yousef Alhindi, Amanda Avery
Contemporary Clinical Trials Communications (2022) Vol. 28, pp. 100944-100944
Open Access | Times Cited: 27
Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Brandon Baer, Nathan D. Putz, Kyle Riedmann, et al.
AJP Lung Cellular and Molecular Physiology (2023) Vol. 325, Iss. 3, pp. L368-L384
Open Access | Times Cited: 13
Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food
Kayla J. Colvin, Henry S. Killen, Maxwell J. Kanter, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9710-9710
Open Access | Times Cited: 37
Reverse epidemiology of obesity paradox: Fact or fiction?
Bellamkonda Kishore
Physiological Reports (2024) Vol. 12, Iss. 21
Open Access | Times Cited: 4
Depression among outpatients with diabetic peripheral neuropathy: prevalence and associated factors
Besher Gharaibeh, Aya Baniyones, Sawsan Abuhammad, et al.
Future Science OA (2025) Vol. 11, Iss. 1
Open Access
Glucagon-like peptide-1 (GLP-1) receptor agonists: applications in childhood diabetes and obesity
Kun Hu, Timothy Barrett
Paediatrics and Child Health (2025)
Closed Access
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Franco Folli, Giovanna Finzi, Roberto Manfrini, et al.
AJP Endocrinology and Metabolism (2023) Vol. 325, Iss. 5, pp. E595-E609
Open Access | Times Cited: 9
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Merle Myerson, Rodis Paparodis
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1204-1221
Closed Access | Times Cited: 3
Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs
Hridish Narayan Chakravarti, Arijit Nag
Journal of Endocrinological Investigation (2020) Vol. 44, Iss. 3, pp. 481-492
Open Access | Times Cited: 27
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
Samson Mathews Samuel, Elizabeth Varghese, Peter Kubatka, et al.
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1580-1580
Open Access | Times Cited: 14
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Stephen Brunton, Ofri Mosenzon, Eugene E. Wright
Postgraduate Medicine (2020) Vol. 132, Iss. sup2, pp. 48-60
Open Access | Times Cited: 21
The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research
Caroline J. Violette, Ravi Agarwal, Rachel S. Mandelbaum, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 4, pp. 385-395
Closed Access | Times Cited: 7
A Review of Oral Semaglutide Available Evidence
AbdulH Zargar, Sanjay Kalra, Sambit Das
Indian Journal of Endocrinology and Metabolism (2022) Vol. 26, Iss. 2, pp. 98-105
Open Access | Times Cited: 10
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Bhavarth P. Dave, Mehul R. Chorawala, Ishika V Shah, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Kalie L. Tommerdahl, Kristen J. Nadeau, Petter Bjornstad
Advances in Chronic Kidney Disease (2021) Vol. 28, Iss. 4, pp. 337-346
Open Access | Times Cited: 10
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations
Ian Blumer, Jeremy Pettus, Tricia Santos Cavaiola
Postgraduate Medicine (2018) Vol. 130, Iss. 4, pp. 375-380
Closed Access | Times Cited: 10
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
Linong Ji, Ying Du, Min Xu, et al.
Diabetologia (2021) Vol. 64, Iss. 5, pp. 1066-1078
Open Access | Times Cited: 9
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
NEIL SKOLNIK, Stefano Del Prato, Lawrence Blonde, et al.
Advances in Therapy (2021) Vol. 38, Iss. 4, pp. 1715-1731
Open Access | Times Cited: 8
An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist
P. Puri, Narendra Kotwal
Journal of Clinical and Experimental Hepatology (2021) Vol. 12, Iss. 2, pp. 560-574
Open Access | Times Cited: 8
Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes
Anna Licata, Giuseppina Russo, Annalisa Giandalia, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top